Oleg Fedorov
PI, Group Head
- Biochemistry and Biophysics
Molecular Biophysics and Biochemistry group in CMD/TDI Oxford specialises on chemical probe discovery projects, especially in the field of Epigenetics and Ubiquitin system. Main target areas are acetyl-lysine reader domains and E3 ligases. The group supports the wide variety of screening assays developed for most of the targets. The in-depth characterization of drug candidates relies on a series of biophysical techniques established for accurate measurements of thermodynamics of and kinetic parameters of binding. The group also supports and extend the focused libraries of small molecular weight ligands for proteins of interest.
Recent publications
-
Binding-Site Purification of Actives (B-SPA) Enables Efficient Large-Scale Progression of Fragment Hits by Combining Multi-Step Array Synthesis With HT Crystallography.
Journal article
Grosjean H. et al, (2025), Angewandte Chemie (International ed. in English)
-
Covalent Inhibitors of S100A4 Block the Formation of a Pro-Metastasis Non-Muscle Myosin 2A Complex
Journal article
Giroud C. et al, (2024), Journal of Medicinal Chemistry, 67, 18943 - 18956
-
Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements
Journal article
Griffen EJ. and Boulet P., (2024), Wellcome Open Research, 9, 374 - 374
-
Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist
Journal article
Balıkçı E. et al, (2024), Journal of Medicinal Chemistry, 67, 7245 - 7259
-
Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.
Journal article
Xiong Y. et al, (2024), Journal of medicinal chemistry, 67, 5837 - 5853